GEO-D03 DNA vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

CompletedNCT01571960

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2012-04-30End: 2016-01-31Updated: 2021-10-15

Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications

WithdrawnNCT01909414

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Updated: 2021-11-11

Related Papers

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults

PLoS ONE2017-07-2033 citations

Recent Advances and Current Status of GM-CSF as an Adjuvant in DNA Vaccines for Viral Diseases

Journal of Investigative Genomics2015-06-16